Literature DB >> 2864478

RU 38486: a potent antiglucocorticoid in vitro and in vivo.

D Gagne, M Pons, D Philibert.   

Abstract

The antiglucocorticoid activity of RU 38486, was studied both in vitro and in vivo. In vitro studies, RU 38486 was characterized by a high affinity (3 times higher than that of dexamethasone) for the cytosolic glucocorticoid receptor in rat hepatoma tissue culture (HTC) cells. This high affinity was due to a very low dissociation rate of the complexes formed with the receptor. In whole cells it was a potent full antagonist of dexamethasone-induced tyrosine aminotransferase (TAT) activity: the IC50 was 6-7 times lower than the concentration of the dexamethasone used. It was devoid of any glucocorticoid activity up to a concentration of 10 microM. In in vivo studies using adrenalectomized rats, RU 38486 totally inhibited dexamethasone-induced hepatic tryptophan oxygenase (TO) activity. It is also the first pure antagonist of dexamethasone-induced hepatic TAT. However, doses as high as 5 mg/kg of body weight were required for a 50% inhibition of the effect of dexamethasone at 0.01 mg/kg. RU 38486 did not display any glucocorticoid effect on these two responses up to 50 mg/kg.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2864478     DOI: 10.1016/0022-4731(85)90401-7

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  33 in total

1.  An analysis of glucocorticoid receptor-mediated gene expression in BEAS-2B human airway epithelial cells identifies distinct, ligand-directed, transcription profiles with implications for asthma therapeutics.

Authors:  T Joshi; M Johnson; R Newton; M Giembycz
Journal:  Br J Pharmacol       Date:  2015-01-08       Impact factor: 8.739

2.  Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2.

Authors:  Kyoung-Jin Min; Ji Hoon Jang; Jung Tae Lee; Kyeong Sook Choi; Taeg Kyu Kwon
Journal:  J Mol Med (Berl)       Date:  2011-10-19       Impact factor: 4.599

3.  Hippocampal cell responses in mice with a targeted glucocorticoid receptor gene disruption.

Authors:  W Hesen; H Karst; O Meijer; T J Cole; W Schmid; E R de Kloet; G Schütz; M Joëls
Journal:  J Neurosci       Date:  1996-11-01       Impact factor: 6.167

4.  The dilemma of foraging herbivores: dealing with food and fear.

Authors:  Clare McArthur; Peter B Banks; Rudy Boonstra; Jennifer Sorensen Forbey
Journal:  Oecologia       Date:  2014-10-01       Impact factor: 3.225

5.  A novel therapeutic approach for treatment of catamenial epilepsy.

Authors:  Suchitra Joshi; Huayu Sun; Karthik Rajasekaran; John Williamson; Edward Perez-Reyes; Jaideep Kapur
Journal:  Neurobiol Dis       Date:  2017-12-21       Impact factor: 5.996

6.  New insight into dexamethasone activity in lymphoblast transformation of mouse thymocytes.

Authors:  B Bertin; J Buré; J L Junien; V Levièvre
Journal:  Agents Actions       Date:  1986-12

7.  Acute oral administration of the novel, competitive and selective glucocorticoid receptor antagonist ORG 34517 reduces the severity of ethanol withdrawal and related hypothalamic-pituitary-adrenal axis activation.

Authors:  Anna R Reynolds; Meredith A Saunders; Honoree' W Brewton; Sydney R Winchester; Ibrahim S Elgumati; Mark A Prendergast
Journal:  Drug Alcohol Depend       Date:  2015-06-22       Impact factor: 4.492

8.  Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486.

Authors:  B E Murphy; D Filipini; A M Ghadirian
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

9.  Progestin inhibition of estrogen-dependent proliferation in ZR-75-1 human breast cancer cells: antagonism by insulin.

Authors:  R Poulin; J M Dufour; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

10.  Differential effect of glucocorticoid receptor antagonists on glucocorticoid receptor nuclear translocation and DNA binding.

Authors:  Francesca Spiga; David M Knight; Susanne K Droste; Becky Conway-Campbell; Yvonne Kershaw; Cliona P MacSweeney; Fiona J Thomson; Mark Craighead; Bernard W M M Peeters; Stafford L Lightman
Journal:  J Psychopharmacol       Date:  2010-01-21       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.